Scarica l'app Stockscreener
369.84
0.41%
-1.53
Dopo l'orario di chiusura:
342.00
-27.84
-7.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$371.37
Aprire:
$370
Volume 24 ore:
260.22K
Relative Volume:
0.74
Capitalizzazione di mercato:
$8.21B
Reddito:
-
Utile/perdita netta:
$-518.67M
Rapporto P/E:
-14.72
EPS:
-25.12
Flusso di cassa netto:
$-438.32M
1 W Prestazione:
+6.97%
1M Prestazione:
+18.87%
6M Prestazione:
+9.68%
1 anno Prestazione:
+51.26%
Intervallo 1D:
$360.00
$371.40
Intervallo di 1 settimana:
$342.73
$375.67
Portata 52W:
$200.63
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Nome
Madrigal Pharmaceuticals Inc
Settore
Industria
Telefono
404-380-9263
Indirizzo
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Confronta MDGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
369.84 | 8.28B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-28 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-06-28 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-04-22 | Iniziato | BofA Securities | Underperform |
| 2024-03-15 | Aggiornamento | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-02-26 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Reiterato | Oppenheimer | Outperform |
| 2022-12-19 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-19 | Reiterato | Piper Sandler | Overweight |
| 2022-12-19 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-11-24 | Ripresa | Evercore ISI | Outperform |
| 2020-11-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-05 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-01-30 | Iniziato | Canaccord Genuity | Buy |
| 2020-01-09 | Aggiornamento | UBS | Neutral → Buy |
| 2019-11-07 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-25 | Iniziato | Stifel | Hold |
| 2019-06-10 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-12-12 | Iniziato | B. Riley FBR | Neutral |
| 2018-11-19 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Iniziato | Citigroup | Buy |
| 2018-08-06 | Downgrade | Goldman | Buy → Neutral |
| 2018-06-28 | Iniziato | Raymond James | Mkt Perform |
Mostra tutto
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Madrigal Pharmaceuticals director Bate sells $3.6M in stock - Investing.com
Assessing Madrigal Pharmaceuticals' Long-Term Market Potential in the LDL-C Lowering Therapy Sector Amid Competitive Dynamics - AInvest
Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further (NASDAQ:MDGL) - Seeking Alpha
Madrigal Pharmaceuticals Grants Equity Awards to New Hires Under Inducement Plan - MSN
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Canaccord Genuity?s 45th Annual Growth Conference, Aug-12-2025 10 - MarketScreener
Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat - MSN
Is Madrigal Pharmaceuticals Inc. stock trending bullishPortfolio Risk Report & Growth Oriented Trading Recommendations - sundaytimes.kr
Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy - MSN
Madrigal Pharmaceuticals Director Buys and Sells Shares Amid Price Volatility. - AInvest
Madrigal Pharmaceuticals director sells $16.6m in stock - Investing.com
Madrigal Pharmaceuticals director Taub sells $16.5 million in stock By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals director Taub sells $16.5 million in stock - Investing.com
Madrigal Pharmaceuticals to Present at Canaccord Genuity Growth Conference - MSN
Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - simplywall.st
S&E In Brief: Launch Updates And Political Headwinds - insights.citeline.com
Piper Sandler reiterates Overweight rating on Madrigal stock amid strong launch - Investing.com Canada
MDGL: UBS Raises Price Target Amidst Steady Buy Ratings | MDGL S - GuruFocus
Jefferies raises Madrigal Pharmaceuticals stock price target to $502 on patent extension - Investing.com Canada
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion - MSN
Party Time: Brokers Just Made Major Increases To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Earnings Forecasts - uk.finance.yahoo.com
Leading vs lagging indicators on Madrigal Pharmaceuticals Inc. performanceSwing Trade Watchlist with Entry Zones - Newser
What to do if you’re stuck in Madrigal Pharmaceuticals Inc.Trade Ideas Based on Fundamental Metrics - Newser
Madrigal Pharmaceuticals Q2 2025 Earnings Preview - MSN
What to expect from Madrigal Pharmaceuticals Inc. in the next 30 daysFree Consistent Income Focused Trade List - Newser
Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Madrigal Pharmaceuticals: Strategic Growth and Market Potential Driven by Rezdiffra’s Success and Key Acquisitions - TipRanks
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2025 Earnings Call Transcript - Insider Monkey
Madrigal signals blockbuster Rezdiffra trajectory as new patent extends exclusivity to 2045 - MSN
MDGL Analyst Rating Update: Canaccord Genuity Raises Price Targe - GuruFocus
Cautious Outlook on Madrigal Pharmaceuticals: Sell Rating Amid Competitive Pressures and Valuation Concerns - TipRanks
Madrigal Pharmaceuticals (MDGL) Stock Target Raised on Strong 2Q Results - GuruFocus
Madrigal Pharmaceuticals shares fall 1.15% premarket after reporting a Q2 net loss of $42.3 million. - AInvest
Madrigal 2025 Q2 Earnings Strong Revenue Surge, Narrowed Losses - AInvest
Madrigal: Q2 Earnings Snapshot - New Haven Register
Madrigal Pharmaceuticals Inc (MDGL) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Madrigal (MDGL) Q2 Revenue Soars 1,313% - AOL.com
Madrigal Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Madrigal Surges 8.59 on 290th-Ranked $410M Volume as Patent Extensions and $212M Rezdiffra Sales Drive Momentum - AInvest
Madrigal Pharmaceuticals (MDGL) Achieves Key Growth Milestones w - GuruFocus
Madrigal Pharmaceuticals' Q2 2025: Contradictions Surrounding GLP-1 Market Impact and Rezdiffra Growth - AInvest
Madrigal Pharmaceuticals stock surges as Goldman reiterates buy on strong sales - Investing.com Canada
Madrigal Pharmaceuticals to Announce Q2 2025 Results with Live Webcast - MSN
Madrigal (MDGL) Q2 Revenue Soars 1,313% - The Motley Fool
Madrigal stock jumps after massive Q2 beat (MDGL:NASDAQ) - Seeking Alpha
Madrigal’s MASH drug handily tops forecasts as execs discuss GLP-1 combos - Endpoints News
Madrigal Pharmaceuticals reports Q2 EPS ($1.90), consensus ($3.53) - TipRanks
GLP-1, Rezdiffra MASH-up eyed in $2B Madrigal/CSPC deal - BioWorld MedTech
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial R - GuruFocus
Madrigal Pharmaceuticals Inc Azioni (MDGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):